Spyglass Pharma (NASDAQ:SGP) Reaches New 12-Month High – Time to Buy?

Posted by Brenda Bartman on Nov 5th, 2026

Spyglass Pharma, Inc. (NASDAQ:SGP – Get Free Report) reached a new 52-week high on Tuesday. The stock traded as high as $34.24 and last traded at $34.6730, with a volume of 1,557 shares traded. The stock had previously closed at $33.64.

Wall Street Analyst Weigh In

SGP has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Spyglass Pharma in a research note on Wednesday, October 21st. Wall Street Zen raised shares of Spyglass Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Raymond James Financial began coverage on shares of Spyglass Pharma in a report on Friday, August 14th. They issued an “outperform” rating and a $39.00 price objective for the company. Weiss Ratings cut shares of Spyglass Pharma from a “sell (e+)” rating to a “sell (e)” rating in a research report on Friday, September 25th. Finally, UBS Group reaffirmed a “buy” rating on shares of Spyglass Pharma in a research note on Monday, October 5th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Spyglass Pharma currently has an average rating of “Moderate Buy” and an average target price of $44.00.

View Our Latest Analysis on Spyglass Pharma

Spyglass Pharma Trading Down 2.2%

The company has a market capitalization of $1.13 billion and a PE ratio of -4.82. The firm’s 50-day simple moving average is $27.69 and its 200-day simple moving average is $24.43.

Spyglass Pharma (NASDAQ:SGP – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.11). As a group, analysts anticipate that Spyglass Pharma, Inc. will post -2.55 EPS for the current year.

Institutional Investors Weigh In On Spyglass Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. First Light Asset Management LLC acquired a new stake in shares of Spyglass Pharma during the 1st quarter worth about $9,716,000. Affinity Asset Advisors LLC purchased a new stake in Spyglass Pharma during the 1st quarter valued at approximately $6,478,000. Monashee Investment Management LLC acquired a new stake in shares of Spyglass Pharma during the first quarter worth $2,461,000. Bank of America Corp DE acquired a new stake in shares of Spyglass Pharma in the 1st quarter worth $726,000. Finally, Bank of New York Mellon Corp acquired a new position in Spyglass Pharma during the 2nd quarter worth approximately $533,000.

Spyglass Pharma Company Profile

(Get Free Report)

SpyGlass Pharma, Inc is an ophthalmic pharmaceutical company developing sustained drug-delivery technologies for the treatment of eye diseases. The company’s platform is designed to provide continuous delivery of medication within the eye, with the goal of reducing reliance on daily topical eye drops and improving treatment adherence.

SpyGlass Pharma’s lead product candidate is an investigational drug-delivery system intended to treat glaucoma and ocular hypertension. The implant is designed to be placed in the eye during cataract surgery and release a therapeutic agent over an extended period, potentially providing longer-term control of elevated intraocular pressure.

The company is advancing its technology through clinical development and regulatory processes in the United States.